Close

pCDCAR1 PSMA h(28ζ) (CAR-ZP027)


All products and services are For Research Use Only and CANNOT be used in the treatment or diagnosis of disease.

The vector of anti-PSMA chimeric antigen receptor (CAR) is constructed for the engineering of T cells to target Human PSMA. The T cells are genetically modified through transduction with a lentiviral vector expressing scFv of anti-PSMA antibody linked to CD28 and CD3ζ signaling domains. And the vector product was designed for the treatment of prostate cancer.

Specific Inquiry

  • Size:
  • Marker:
  • Form:
  Add to Cart

Details

  • Target
  • PSMA
  • Targeting Cell Type
  • T cell
  • Targeting Diseases
  • Prostate cancer
  • Generation
  • Second
  • Vector Name
  • pCDCAR1
  • Vector Length
  • ~8kb
  • Vector Type
  • Lentiviral vector
  • Receptor Construction
  • scFv-CD28-CD3ζ
  • Discription of Signaling Cassetes
  • CD28
    CD28 (Cluster of Differentiation 28) is one of the proteins expressed on T cells that provide co-stimulatory signals required for T cell activation and survival. CD28 is the receptor for CD80 (B7.1) and CD86 (B7.2) proteins which are expressed on antigen-presenting cells (APC). CD28 modulates the primary TCR/CD3ζ signal in a different fashion than the late costimulatory elements OX40 and 4-1BB. CD28 enhances the expression of downstream regulators that impact on T-cell proliferation, death, differentiation, and effector functions. CAR T cell containing the CD28 endodomain showed strikingly enhanced sustained T cell activation, growth, survival. And CD28 results in a brightly expressed, stable receptor as the transmembrane domain. Including CD28 costimulatory domains in CARs led to enhanced anti-malignancy efficacy.
    CD3ζ
    CD3ζ, also known as T-cell receptor zeta, which together with T-cell receptor and CD3γ, δ, ε chain, forms the TCR-CD3 complex. ζ was expressed independently from the complex. The zeta chain plays an important role in coupling antigen recognition to several intracellular signal-transduction pathways. CD3-zeta, which contains 3 ITAMs, is the most commonly used endodomain component of CARs. It transmits an activation signal to the T cell after antigen is bound. CD3-zeta may not provide a fully competent activation signal and additional co-stimulatory signaling is needed. For example, chimeric CD28 and OX40 can be used with CD3-zeta to transmit a proliferative/survival signal, or all three can be used together.

Target

  • Clone
  • 3D8
  • Host
  • Mouse
  • Target Species
  • Human
  • Gene Name
  • PSMA
  • Synonyms
  • FOLH1, PSMA, GIG27, FOLH, NAALAD1, PSM, NAALADase I, GCPII, FGCP

Customize Your CAR Products

Cannot find the desired product? Don't worry, just try our online CAR and CAR cell customizing system, which offers full options to meet all unique needs, including but not limited to conventional or unconventional CAR constructs, as well as a variety of vectors and cells. The customization process can be completed with just a few simple clicks, please feel free to try it out.
CAR and CAR Cell Customizing System
  • Published Data
Complete CAR data FCM

Fig.1 Detection of PSMA cell surface expression on PC3-PSMA cells by 3D8 mAb.

CAR Construction : 3D8 scFv-28ζ Latest CAR Construction

Fig.1 Detection of PSMA cell surface expression on PC3-PSMA cells by 3D8 mAb.

PC3 and PC3-PSMA cellswere analyzedby flowcytometry staining with 3D8 mAb followed by incubation with secondary PE-conjugated anti-mouse IgG antibody (solid line).

Ma, Q., Gomes, E. M., Lo, A. S. Y., & Junghans, R. P. (2014). Advanced generation anti‐prostate specific membrane antigen designer T Cells for prostate cancer immunotherapy. The prostate, 74(3), 286-296.

Complete CAR data FCM

Fig.2 Expression of anti-PSMA CARs in T cells.

CAR Construction : 3D8 scFv-28ζ Latest CAR Construction

Fig.2 Expression of anti-PSMA CARs in T cells.

Expression of IgTCR and IgCD28 TCR.

Ma, Q., Gomes, E. M., Lo, A. S. Y., & Junghans, R. P. (2014). Advanced generation anti‐prostate specific membrane antigen designer T Cells for prostate cancer immunotherapy. The prostate, 74(3), 286-296.

Complete CAR data WB

Fig.3 Homodimer formation of IgTCR and IgCD28 TCR.

CAR Construction : 3D8 scFv-28ζ Latest CAR Construction

Fig.3 Homodimer formation of IgTCR and IgCD28 TCR.

Positions of monomer and dimer of TCRz, IgTCR and IgCD28 TCR are indicated on the right. Molecular mass markers (kDa) are indicated on the left.

Ma, Q., Gomes, E. M., Lo, A. S. Y., & Junghans, R. P. (2014). Advanced generation anti‐prostate specific membrane antigen designer T Cells for prostate cancer immunotherapy. The prostate, 74(3), 286-296.

Complete CAR data ELISA

Fig.4 Superior cytokine production by 2ndgen dTc.Non-transduced,IgTCR andIgCD28 TCR transduced T cells were incubated with control PC3 and PC3-PSMA tumor cells for 24 hr.

CAR Construction : 3D8 scFv-28ζ Latest CAR Construction

Fig.4 Superior cytokine production by 2ndgen dTc.Non-transduced,IgTCR andIgCD28 TCR transduced T cells were incubated with control PC3 and PC3-PSMA tumor cells for 24 hr.

Supernatants were harvested and assayed for IL2 and IFNg by ELISA.

Ma, Q., Gomes, E. M., Lo, A. S. Y., & Junghans, R. P. (2014). Advanced generation anti‐prostate specific membrane antigen designer T Cells for prostate cancer immunotherapy. The prostate, 74(3), 286-296.

Complete CAR data FuncS

Fig.5 Proliferation of dTc in response to PSMAþ tumor cells.

CAR Construction : 3D8 scFv-28ζ Latest CAR Construction

Fig.5 Proliferation of dTc in response to PSMAþ tumor cells.

Total cell proliferation.Non-transduced control,IgTCR and IgCD28TCR transduced T cells with 45% transduction efficiency for both were stimulated with g-irradiated PC3 and PC3-PSMA tumor cells for 3 days,cultured for a further 6 days, and counted on days noted.

Ma, Q., Gomes, E. M., Lo, A. S. Y., & Junghans, R. P. (2014). Advanced generation anti‐prostate specific membrane antigen designer T Cells for prostate cancer immunotherapy. The prostate, 74(3), 286-296.

Complete CAR data FuncS

Fig.6 GD2 sugar moiety and correlation of anti-GD2 mAb affinity with clinical efficacy.

CAR Construction : 3D8 scFv-28ζ Latest CAR Construction

Fig.6 GD2 sugar moiety and correlation of anti-GD2 mAb affinity with clinical efficacy.

Data are represented as mean±s.d.

Hassani, M., Hajari Taheri, F., Sharifzadeh, Z., Arashkia, A., Hadjati, J., van Weerden, W. M., ... & Abolhassani, M. (2019). Construction of a chimeric antigen receptor bearing a nanobody against prostate a specific membrane antigen in prostate cancer. Journal of Cellular Biochemistry, 120(6), 10787-10795.

Complete CAR data FCM

Fig.7 Schematic presentation of NBPII‐CAR and expression of NBPII‐CAR on electroporated T cells.

CAR Construction : 3D8 scFv-28ζ Latest CAR Construction

Fig.7 Schematic presentation of NBPII‐CAR and expression of NBPII‐CAR on electroporated T cells.

Tumor cells were stained with PE-conjugated anti-PSMA antibody or isotype control antibody and analyzed by flow cytometry.

Hassani, M., Hajari Taheri, F., Sharifzadeh, Z., Arashkia, A., Hadjati, J., van Weerden, W. M., ... & Abolhassani, M. (2019). Construction of a chimeric antigen receptor bearing a nanobody against prostate a specific membrane antigen in prostate cancer. Journal of Cellular Biochemistry, 120(6), 10787-10795.

Complete CAR data ELISA

Fig.8 Recognition of PSMA as target cells.

CAR Construction : 3D8 scFv-28ζ Latest CAR Construction

Fig.8 Recognition of PSMA as target cells.

After 24 hours of coculturing T cells with target cells (PSMA+ LNCaP and PSMA− DU-145 cells at E:T ratios 1:1 and 3:1.

Hassani, M., Hajari Taheri, F., Sharifzadeh, Z., Arashkia, A., Hadjati, J., van Weerden, W. M., ... & Abolhassani, M. (2019). Construction of a chimeric antigen receptor bearing a nanobody against prostate a specific membrane antigen in prostate cancer. Journal of Cellular Biochemistry, 120(6), 10787-10795.

Complete CAR data FuncS

Fig.9 Proliferation of engineered T cells upon encountering PSMA.

CAR Construction : 3D8 scFv-28ζ Latest CAR Construction

Fig.9 Proliferation of engineered T cells upon encountering PSMA.

Data are normalized with the growth rate of negative control cell and reported as a percentage.

Hassani, M., Hajari Taheri, F., Sharifzadeh, Z., Arashkia, A., Hadjati, J., van Weerden, W. M., ... & Abolhassani, M. (2019). Construction of a chimeric antigen receptor bearing a nanobody against prostate a specific membrane antigen in prostate cancer. Journal of Cellular Biochemistry, 120(6), 10787-10795.

More Published Data More Published Data

Customer Reviews and Q&As

There are currently no customer reviews or questions for Anti-PSMA (3D8) h(CD28-CD3ζ) CAR, pCDCAR1 (CAR-ZP027). Click the button below to contact us or submit your feedback about this product.

For research use only. Not intended for any clinical use. No products from Creative Biolabs may be resold, modified for resale or used to manufacture commercial products without prior written approval from Creative Biolabs.

Related Products

Online Inquiry

For any technical issues or product/service related questions, please leave your information below. Our team will contact you soon.

This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Key Updates
Newsletter NEWSLETTER

The latest newsletter to introduce the latest breaking information, our site updates, field and other scientific news, important events, and insights from industry leaders

LEARN MORE NEWSLETTER
New Solution NEW SOLUTION

CellRapeutics™ In Vivo Cell Engineering: One-stop in vivo T/B/NK cell and macrophage engineering services covering vectors construction to function verification.

LEARN MORE SOLUTION
NOVEL SOLUTION NOVEL TECHNOLOGY

Silence™ CAR-T Cell: A novel platform to enhance CAR-T cell immunotherapy by combining RNAi technology to suppress genes that may impede CAR functionality.

LEARN MORE NOVEL TECHNOLOGY
NEW TECHNOLOGY NEW SOLUTION

Canine CAR-T Therapy Development: From early target discovery, CAR design and construction, cell culture, and transfection, to in vitro and in vivo function validation.

LEARN MORE SOLUTION
Receive our latest news and insights.